Get the Stockscreener App
81.02
5.54%
-5.14
Monopar Therapeutics Inc stock is traded at $81.02, with a volume of 81,799.
It is down -5.54% in the last 24 hours and down -18.11% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$86.16
Open:
$86.16
24h Volume:
81,799
Relative Volume:
1.24
Market Cap:
$502.42M
Revenue:
-
Net Income/Loss:
$-7.12M
P/E Ratio:
-35.23
EPS:
-2.3
Net Cash Flow:
$-6.82M
1W Performance:
+0.18%
1M Performance:
-18.11%
6M Performance:
+81.02%
1Y Performance:
+456.31%
1-Day Range:
$77.00
$86.16
1-Week Range:
$77.00
$89.86
52-Week Range:
$13.94
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
81.43 | 531.60M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.61 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.67 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.67 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.12 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.31 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
What moving averages say about Monopar Therapeutics Inc.2025 Geopolitical Influence & Long Hold Capital Preservation Tips - newser.com
Is Monopar Therapeutics Inc. stock entering bullish territory2025 Analyst Calls & Real-Time Buy Zone Alerts - newser.com
Top chart patterns to watch in Monopar Therapeutics Inc.Market Risk Analysis & Low Volatility Stock Suggestions - newser.com
Monopar Therapeutics Inc. stock prediction for this weekQuarterly Market Review & Accurate Buy Signal Notifications - newser.com
Why Monopar Therapeutics Inc. stock attracts global investorsWeekly Trend Recap & Verified Short-Term Plans - newser.com
How Monopar Therapeutics Inc. (1IY0) stock reacts to monetary easingPortfolio Update Report & Expert Curated Trade Ideas - newser.com
Is Monopar Therapeutics Inc. stock attractive for retirement portfoliosWeekly Risk Report & Community Consensus Trade Signals - newser.com
Is Monopar Therapeutics Inc. forming a reversal patternQuarterly Portfolio Report & Target Return Focused Picks - newser.com
Has Monopar Therapeutics Inc. formed a bullish divergenceWeekly Profit Summary & Low Risk High Win Rate Picks - newser.com
Why Monopar Therapeutics Inc. stock remains a top recommendationJuly 2025 Highlights & Smart Swing Trading Alerts - newser.com
Will Monopar Therapeutics Inc. stock deliver long term returns2025 Sector Review & Risk Adjusted Buy/Sell Alerts - newser.com
Multi factor analysis applied to Monopar Therapeutics Inc.Wall Street Watch & Risk Managed Investment Signals - newser.com
Exit strategy if you’re trapped in Monopar Therapeutics Inc.Weekly Earnings Recap & Weekly Return Optimization Alerts - newser.com
Monopar Therapeutics (NASDAQ:MNPR) Sees Unusually-High Trading VolumeHere's Why - MarketBeat
Heatmap analysis for Monopar Therapeutics Inc. and competitorsJuly 2025 Decliners & Verified Swing Trading Watchlists - newser.com
When is the best time to exit Monopar Therapeutics Inc.Weekly Loss Report & High Return Stock Watch Alerts - newser.com
Applying sector rotation models to Monopar Therapeutics Inc.Watch List & Verified Technical Trade Signals - newser.com
Monopar Therapeutics Inc. (MNPR) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Monopar Therapeutics’ Innovative Imaging Agent Study: Market Implications - TipRanks
Monopar Therapeutics (MNPR) Price Target Increased by 14.64% to 113.81 - Nasdaq
How risky is Monopar Therapeutics Inc. (1IY0) stock compared to peersTrade Ideas & High Conviction Buy Zone Picks - fcp.pa.gov.br
Aug Closing: How Monopar Therapeutics Inc. (1IY0) stock benefits from digital adoptionJuly 2025 Action & Entry Point Confirmation Alerts - fcp.pa.gov.br
Monopar Therapeutics (FRA:1IY0) EV-to-EBIT : -21.79 (As of Oct. 27, 2025) - GuruFocus
Is Monopar Therapeutics Inc. stock attractive for income investorsJuly 2025 Trends & Growth Focused Stock Pick Reports - fcp.pa.gov.br
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Monopar Therapeutics Inc Stock (MNPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tsuchimoto Kim R | Director |
Jul 14 '25 |
Sale |
40.00 |
8,904 |
356,171 |
11,486 |
| STARR CHRISTOPHER M | Director |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
5,173 |
| Robinson Chandler | Chief Executive Officer |
Jul 14 '25 |
Sale |
40.00 |
16,800 |
672,020 |
73,472 |
0.17%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):